A. Barreiro

发表

Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial.

J. Blanco, B. Trinité, L. Leal, 2022, medRxiv.

Diets of marine mammals stranded on the northwestern Spanish Atlantic coast with special reference to Cephalopoda

Alfredo López, Á. Guerra, Á. F. González, 1994 .

Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine candidate based on a novel recombinant RBD fusion heterodimer of SARS-CoV-2

J. Barretina, B. Clotet, J. Segalés, 2021 .

Preclinical efficacy, safety, and immunogenicity of PHH-1V, a second-generation COVID-19 vaccine, in non-human primates

S. Marfil, A. Meyerhans, M. Cañete, 2022 .

Use of chemostat cultures mimicking different phases of wine fermentations as a tool for quantitative physiological analysis

P. Ferrer, J. Albiol, R. Gonzalez, 2014, Microbial Cell Factories.

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

S. Marfil, A. Meyerhans, M. Cañete, 2023, bioRxiv.

Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform—Analysis of Production and Immunogenicity

B. Clotet, J. Blanco, J. Carrillo, 2023, International journal of molecular sciences.

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

A. Borobia, B. Clotet, J. Prado, 2022, The Lancet Regional Health - Europe.

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

J. Segalés, S. Marfil, A. Meyerhans, 2023, bioRxiv.